Purpose. Medication treatment patterns for chronic obstructive pulmonary disease (COPD) in inpatient settings were examined, as were the characteristics of patients treated with long-acting bronchodilators (LABDs) during hospitalization.
C hronic lower-respiratory-tract disease, which includes chronic obstructive pulmonary disease (COPD), is the third leading cause of death in the United States. 1 COPD is a progressive, irreversible disease characterized by persistent airflow limitation. 2 Acute exacerbations contribute to COPD severity, lead to increased symptoms, and require a change in drug therapy. 2 COPD imposes a significant economic burden, largely driven by exacerbations. 3 COPD exacerbations account for approximately 700,000 hospitalizations each year in the United States 4 and 10-fold higher annual healthcare costs compared with patients who have no exacerbations. 5 Although COPD cur-rently cannot be cured, it can be managed with appropriate treatment. 2, 6 Treatment of acute exacerbations and prevention of future exacerbations are key to managing COPD. Patients with frequent exacerbations experience an accelerated decline in lung function, which is typically measured by forced expiratory volume. [7] [8] [9] Frequent exacerbations are also associated with decreased health-related quality of life and increased mortality risk. 9 Severe exacerbations necessitating hospitalization increase the risk of mortality, with each subsequent hospitalization further increasing mortality risk. 10 With COPD progression, exacerbations become more frequent and severe; the greatest predictor of future exacerbations is a history of previous exacerbations. 11 Therefore, prevention of exacerbations is an important goal of COPD management.
Prevention, treatment, and management of COPD exacerbations require different pharmacologic approaches. Moderate-to-severe acute exacerbations are typically treated with short-acting bronchodilators (SABDs), sometimes in conjunction with systemic or oral corticosteroids, antibiotics, oxygen, or other treatments. 2, 12 Treatment with SABDs is considered the cornerstone in managing acute symptoms and airflow obstruction. 12 Systemic corticosteroids may improve symptoms and lung function and reduce recovery time and the duration of hospitalization. 2 Maintenance treatment to prevent future exacerbations involves longacting bronchodilators (LABDs) such as long-acting b-agonists (LABAs) and long-acting muscarinic antagonists. 2, 12 Treatment with LABAs or long-acting muscarinic antagonists typically reduces exacerbation rates by approximately 15%. Additional maintenance therapies that may be beneficial in reducing exacerbations include the combination of inhaled corticosteroids and LABAs (26-35% reduction), phosphodiesterase-4 (PDE4) inhibitors such as roflumilast (17% reduction), and prophylactic use of antibiotics (20% reduction) to prevent infectious exacerbations. 12 Patients started on maintenance medication have a lower risk of rehospitalization and a greater mean time to all-cause hospitalization than do those who are not started on maintenance treatment. 13 An important consideration for pharmacologic therapy is the method of administration (dry-powder inhalers, metereddose inhalers, nebulizers), which can affect adherence and adequate delivery of the medication to the lungs. The therapy and device chosen are largely driven by patient preference and response to treatment.
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines provide recommendations for inpatient management of COPD exacerbations. 2 The recommendations include the use of SABDs (e.g., short-acting b-agonists [SABAs], the combination of an SABA and a short-acting muscarinic antagonist [SAMA]), oral or i.v. corticosteroids, bronchodilators delivered with spacers or by air-driven nebulizers, and antibiotics when appropriate. In addi-
KEY POINTS
• Chronic obstructive pulmonary disease (COPD) causes significant morbidity, mortality, and economic burden, largely due to exacerbations.
• Guidelines recommend that patients with COPD be started on maintenance therapy before discharge from exacerbationrelated hospitalization.
• Most COPD patients hospitalized for exacerbations were treated with short-acting bronchodilators; approximately half of patients received maintenance therapy before discharge, despite national guidelines.
tion, initiation of LABD therapy, with or without an inhaled corticosteroid, is recommended before discharge. The primary objective of this study was to examine treatment patterns in patients hospitalized with COPD. A secondary objective was to identify characteristics that differentiated patients treated with LABDs from those treated with only SABDs during hospitalization.
Methods
Study design. This retrospective cohort study used data collected by the administrative hospital database maintained by Premier (Charlotte, NC), the largest hospital-and medical center-based, service-level database in the United States. The database contains detailed service information for more than 500 hospitals and over 50 million inpatient discharges since 2000 and includes patient demographic characteristics, insurance type, hospital characteristics, diagnoses (using International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM] codes), and detailed services (more than 55,000 codes) such as treatment types and dates. The database did not include any identifiable protected health information; therefore, this study did not require institutional review board approval.
Patient selection. This analysis was restricted to patients discharged from the hospital from January 1, 2010, through December 31, 2012. Patients with COPD were identified using criteria similar to those used in previous administrative studies. [13] [14] [15] [16] All patients were required to be age 40 years or older and have either a primary COPD diagnosis (ICD-9-CM code 491.xx, 492.xx, or 496.xx) or a primary diagnosis of a respiratory condition (ICD-9-CM codes 460.xx-519.xx) with a secondary diagnosis of COPD. Exclusion criteria included any diagnosis of asthma (ICD-9-CM code 493. xx), no treatment with a bronchodilator, death during hospitalization, and length of stay exceeding 14 days.
Operational definitions. The Charlson Comorbidity Index, a measure of overall comorbidity that is predictive of mortality, was calculated as a severity weighted sum of 17 different conditions using algorithms designed for administrative data. 17 Current tobacco use was identified based on an ICD-9-CM code of 305.1x. Medications were coded based on the charge master descriptions and included SABAs (albuterol, levalbuterol), LABAs (formoterol, arformoterol, salmeterol), a SAMA (ipratropium), long-acting muscarinic antagonists (tiotropium, glycopyrronium), methylxanthines (theophylline, aminophylline), a PDE4 inhibitor (roflumilast), inhaled corticosteroids (beclomethasone, budesonide, ciclesonide, flunisolide, fluticasone, mometasone, triamcinolone delivered via an inhaler or nebulizer), and systemic corticosteroids (dexamethasone, methylprednisolone, prednisone, prednisolone administered orally or parenterally). Combination products were grouped as unique medication classes and included the combination of an LABA and inhaled corticosteroid (formoterolbudesonide, formoterol-mometasone, salmeterol-fluticasone) and SABA-SAMA (albuterol-ipratropium).
To simplify the description of treatment patterns, respiratory medications were grouped into 8 categories: arformoterol, formoterol, ipratropium, tiotropium, salmeterol-fluticasone, albuterol-ipratropium, any SABA (albuterol or levalbuterol), and miscellaneous maintenance respiratory medications (methylxanthines, PDE4 inhibitors, glycopyrronium, salmeterol, formoterol-budesonide, formoterolmometasone). A treatment-sequencing analysis examined the most common initial and final bronchodilator regimens. Any combination of these was considered a different regimen. The initial regimen was based on the first day the patient received bronchodilators, and the final regimen was based on the last day the patient received bronchodilators. Patients receiving LABDs were defined as those receiving LABAs, long-acting muscarinic antagonists, the combination of an LABA and inhaled corticosteroid, methylxanthine, or PDE4 inhibitors at any point during hospitalization.
Statistical methods. For the treatment patterns analysis, COPDrelated inpatient admissions between 2010 and 2012 served as the unit of analysis. The analysis was descriptive in nature and included means, standard deviations, percentages, and number of observations.
The secondary analysis, predicting treatment with LABDs versus no LABDs, was restricted to COPDrelated inpatient admissions during 2012, with the medical records used to identify prior hospitalizations. Logistic regression with a backward selection procedure was used. Covariates were the number of prior hospitalizations and hospitalization in the last 30 days, which were used as markers for COPD progression; demographics, payer type, and hospital characteristics; tobacco use diagnosis; and service use variables such as oxygen therapy, mechanical ventilation, continuous positive airway pressure or bilevel positive airway pressure, blood gas assessment, spirometry, and intensive care unit admission. The overall accuracy of the model was assessed using the C-statistic (also known as the area under the receiver operating characteristic curve) that indicates the probability that the predicted value from the model would accurately discriminate a randomly selected patient treated with an LABD from a randomly selected patient not receiving an LABD. The C-statistic ranges from 0.5 (complete chance) to 1.0 (perfect classification). All analyses were completed using SAS, version 9.4 (SAS Institute, Cary, NC).
Results
The initial sample consisted of 550,431 inpatient admissions that met the COPD diagnostic criteria. After sequentially excluding admissions with age of <40 years (n = 5,680), length of stay of >14 days (n = 27,128), no bronchodilator treatment (n = 59,992), and death during hospitalization (n = 16,254), the final sample comprised 441,377 COPD-related inpatient admissions, including 51.2% (n = 225,806) with a primary diagnosis of COPD. In this sample, most patients were older (mean age, 69.8 years) and covered by Medicare (74.4%, n = 328,309). The mean length of stay was 4.8 days. The majority of patients were white (78.1%, n = 344,584), and half were from the southern United States (Table 1) .
Medication use. During hospitalization, most patients (95.3%, n = 420,797) received SABDs (SABAs, SAMAs, or a combination product containing both), which were most commonly delivered via nebulizer (89.5%) ( Table 2 ). Approximately half (47.8%, n = 211,134) received only SABDs, and the other 52.2% (n = 230,243) received at least 1 LABD. LABAs were the most common LABDs, used by 39.2% (n = 172,918) of patients at some point during hospitalization. Among LABAtreated patients, 96.7% (n = 167,282) received inhaled corticosteroids either individually or as part of a combination treatment. Only 1.6% of patients (n = 7,006) received nebulized LABAs; 68.4% (n = 4,789) of those receiving Table 2 . nebulized LABAs also received inhaled corticosteroids. On average, patients were started on LABDs a mean ± S.D. of 1.9 ± 1.6 days after admission and on SABDs 1.3 ± 0.9 days after admission. Most patients (80.9%, n = 357,070) received systemic corticosteroids. Almost all (91.6%, n = 404,438) were treated with antibiotics. A majority of patients (78.6%, n = 347,019) were treated with multiple bronchodilators during hospitalization, and the mean ± S.D. number of bronchodilators used was 2.5 ± 1.2. The mean ± S.D. numbers of bronchodilators used by patients treated with only LABDs (4.7%, n = 20,580), only SABDs (47.8%, n = 210,793), and both SABDs and LABDs (47.6%, n = 210,004) were 1.3 ± 0.5, 1.8 ± 0.7, and 3.3 ± 1.0, respectively. Very few patients treated with ipratropium (2.8%) did not receive SABAs. About 40% (range, 39.9-42.8%) of patients receiving treatment with an LABA or combination treatment with an LABA and inhaled corticosteroid also received tiotropium during their hospital stay.
Common treatment sequences. There are many possible bronchodilator treatment regimens. In order to help characterize the sequencing of treatments, we examined only the 5 most commonly used initial treatments, which accounted for 65.6% of admissions (n = 289,705) ( Table 3) : ipratropium plus an SABA, ipratropium-albuterol, an SABA alone, ipratropium-albuterol plus an SABA, and fluticasone-salmeterol plus ipratropium plus an SABA. Four of these included only SABDs or ipratropium plus an SABA. Initial treatments were often continued throughout the hospital stay. LABDs were not a common final therapy across the 5 most common initial treatments.
Predictors of LABD use. Among 146,887 admissions in 2012, 52.5% of patients (n = 77,132) were treated with LABDs at some time during their hospital stay. These patients were significantly different from those not treated with LABDs (Figure 1) . LABD-treated patients had more primary COPD Figure 1 . Odds ratios from logistic regression predicting long-acting bronchodilator (LABD) use. Reference categories for multilevel categorical variables were as follows: race, white; married, married; payer, Medicare; and region, south. Age, hospital size, Charlson comorbidity index (CCI), length of stay (LOS), and prior hospitalizations were numeric variables. SABD = short-acting bronchodilator, ICU = intensive care unit, CPAP = continuous positive airway pressure, BiPAP = bilevel positive airway pressure, COPD = chronic obstructive pulmonary disease. diagnoses, more prior all-cause hospitalizations, longer lengths of stay, fewer comorbidities, and greater spirometry use. Those not treated with LABDs were more likely to be older, be self-paying, require a ventilator, and spend at least 1 night in the intensive care unit. Although there were several statistically significant predictors, the overall accuracy of the model based on the C-statistic was only 0.61. This indicates that the model could accurately discriminate a randomly selected LABD user from a randomly selected non-LABD user 61% of the time.
Discussion
To the best of our knowledge, this is the first analysis characterizing real-world inpatient treatment patterns for COPD. Patterns were complex; most patients were treated with multiple bronchodilators, usually including a short-acting agent. Inhaled bronchodilators were typically given in nebulized formulations, which may be easier to use for sicker, older patients or patients with poor inspiratory force. 18 Consistent with GOLD treatment guidelines for acute exacerbations, most patients received SABAs (95%), systemic corticosteroids (81%), and antibiotics (92%); however, only half were treated with LABDs before discharge. Although significant differences in characteristics were observed between patients receiving or not receiving LABDs in this very large sample, the C-statistic for the model was below the threshold (0.70) for accurate discrimination, 19 suggesting that many patients treated with or without LABDs have relatively similar clinical profiles.
Previous studies examining the concordance between treatment guidelines and hospital treatment of acute COPD exacerbations have reported similar results. Using the same database from an earlier period, Lindenauer and colleagues 14 found that 97% of patients received bronchodilators, 85% received systemic corticosteroids, and 85% received antibiotics. Further, a chart review of New York City hospitals revealed that 94% of patients received bronchodilators, 85% received systemic corticosteroids, and 80% received antibiotics. 20 Although we could not confirm the severity of patients' COPD using the Premier database, our findings were very consistent with those of the studies mentioned. 14, 20 Although methods varied across the studies, the results collectively suggest that inpatient treatment of acute COPD exacerbations is largely consistent with guidelines, though there may still be some room for improvement.
In the outpatient setting, a surprising number of patients with COPD do not receive maintenance treatment; patients with a mild form of the disease may not require COPD maintenance therapy. Using managed care or Medicare administrative claims data, Make and colleagues 21 found that most patients (59.1%) with COPD received no COPD medication. An analysis of private-payer claims data revealed that although 74% of patients in the study sample received COPD pharmacotherapy (rescue or maintenance), only 45% of them received maintenance treatment. 22 Examinations of outpatient treatment for COPD have consistently found that a remarkable number of patients do not receive maintenance therapy.
GOLD treatment guidelines recommend that patients hospitalized for an exacerbation be started on long-acting therapy before hospital discharge. 2 Acute exacerbations have been found to be an important trigger for treatment initiation. 23 In the current analysis, prior hospitalizations were a predictor of LABD use. Bollu and colleagues 13 found that inpatients treated with nebulized LABAs had a lower risk of readmission than did those treated with nebulized SABAs. Although LABDs do not appear to affect outcomes during hospitalization, 15 initiating LABD treatment before discharge may reduce future exacerbations.
Data were collected for administrative rather than research purposes, which may be a limitation of this study. The analysis of administrative data allows for a large sample size and completely unobtrusive research. However, data were not collected in a rigorous fashion, and there may have been some coding errors. Diagnoses in administrative data are not validated with the same level of precision as during controlled research. Admissions for COPD with no bronchodilator treatment or that were associated with a length of stay exceeding 14 days were excluded due to the potential for diagnostic miscoding; the results do not generalize these unusual COPD admissions. Information on outpatient treatment was not available; therefore, no evaluation of outpatient follow-up was possible. The relationship between outpatient LABD use before hospitalization and during hospitalization also could not be examined. The data were collected from 2010 through 2012 and are somewhat dated. In addition, the data collected did not include treatments launched after the study period, the impact of cost on prescriptions, and information regarding patient inhaler proficiency.
Conclusion
A review of COPD-related inpatient admissions found that the majority of patients received the primary recommended treatments for acute exacerbations of COPD (SABAs, systemic corticosteroids, and antibiotics). However, maintenance therapy had been initiated for only about half of patients before discharge.
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